Zobrazeno 81 - 90
of 252
pro vyhledávání: '"Ekaterina S Jordanova"'
Autor:
Pieter A. van der Velden, Martine J. Jager, Daniëlle Krijgsman, Dirk M. van der Steen, Renate S. Hagedoorn, Gregorius P M Luyten, Mehmet Dogrusöz, J. William Harbour, Mirjam H.M. Heemskerk, Gülçin Gezgin, Jinfeng Cao, Matthew G. Field, Karoly Szuhai, Ekaterina S. Jordanova, Sietse J. Luk
Publikováno v:
JAMA Ophthalmology, 135(6)
Gezgin, G, Luk, S J, Cao, J, Dogrusoz, M, van der Steen, D M, Hagedoorn, R S, Krijgsman, D, van der Velden, P A, Field, M G, Luyten, G P M, Szuhai, K, Harbour, J W, Jordanova, E S, Heemskerk, M H M & Jager, M J 2017, ' PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma ', Jama ophthalmology, vol. 135, no. 6, pp. 541-549 . https://doi.org/10.1001/jamaophthalmol.2017.0729
Jama ophthalmology, 135(6), 541-549. American Medical Association
Gezgin, G, Luk, S J, Cao, J, Dogrusoz, M, van der Steen, D M, Hagedoorn, R S, Krijgsman, D, van der Velden, P A, Field, M G, Luyten, G P M, Szuhai, K, Harbour, J W, Jordanova, E S, Heemskerk, M H M & Jager, M J 2017, ' PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma ', Jama ophthalmology, vol. 135, no. 6, pp. 541-549 . https://doi.org/10.1001/jamaophthalmol.2017.0729
Jama ophthalmology, 135(6), 541-549. American Medical Association
Importance Uveal melanoma (UM) is an intraocular primary malignant neoplasm that often gives rise to metastatic disease for which there are no effective therapies. A substantial proportion of UMs express the cancer-testis antigen PRAME (preferentiall
Autor:
Gert Jan Fleuren, Frans A. Prins, Ekaterina S. Jordanova, Arko Gorter, Michelle Osse, J. Baptist Trimbos, Marlies Schrevel
Publikováno v:
International Journal of Oncology
International Journal of Oncology, 50(6), 1947-1954
International Journal of Oncology, 50(6), 1947-1954. Spandidos Publications
Schrevel, M, Osse, E M, Prins, F A, Trimbos, J B M Z, Fleuren, G J, Gorter, A & Jordanova, E S 2017, ' Autocrine expression of the epidermal growth factor receptor ligand heparin-binding EGF-like growth factor in cervical cancer ', International Journal of Oncology, vol. 50, no. 6, pp. 1947-1954 . https://doi.org/10.3892/ijo.2017.3980
International Journal of Oncology, 50(6), 1947-1954
International Journal of Oncology, 50(6), 1947-1954. Spandidos Publications
Schrevel, M, Osse, E M, Prins, F A, Trimbos, J B M Z, Fleuren, G J, Gorter, A & Jordanova, E S 2017, ' Autocrine expression of the epidermal growth factor receptor ligand heparin-binding EGF-like growth factor in cervical cancer ', International Journal of Oncology, vol. 50, no. 6, pp. 1947-1954 . https://doi.org/10.3892/ijo.2017.3980
In cervical cancer, the epidermal growth factor receptor (EGFR) is overexpressed in 70-90% of the cases and has been associated with poor prognosis. EGFR-based therapy is currently being explored in cervical cancer. We investigated which EGFR ligand
Autor:
Rosa S. Djajadiningrat, Jeroen de Jong, Sarah R. Ottenhof, Helene Thygesen, Ekaterina S. Jordanova, Simon Horenblas
Publikováno v:
The Journal of Urology, 197(3), 690-696. Elsevier Inc.
Ottenhof, S R, Djajadiningrat, R S, de Jong, J, Thygesen, H H, Horenblas, S & Jordanova, E S 2017, ' Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status ', The Journal of Urology, vol. 197, no. 3, pp. 690-696 . https://doi.org/10.1016/j.juro.2016.09.088
Ottenhof, S R, Djajadiningrat, R S, de Jong, J, Thygesen, H H, Horenblas, S & Jordanova, E S 2017, ' Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status ', The Journal of Urology, vol. 197, no. 3, pp. 690-696 . https://doi.org/10.1016/j.juro.2016.09.088
PD-L1 (programmed death ligand 1) inhibits T-cell function and prevents tumor eradication. This is facilitated by PD-L1 positive tumor cells and PD-L1 positive immune cells, and can be prevented by anti-PD-1 (programmed death 1)/PD-L1 immunotherapy.
Autor:
Esther Korpershoek, Eleonora P M Corssmit, Cees J. Cornelisse, Henri J L M Timmers, Jeroen C. Jansen, Adrian Bateman, Erik F. Hensen, Ekaterina S. Jordanova, Jean-Pierre Bayley, Peter Devilee, Diana Eccles, Henricus P. M. Kunst, Attje S. Hoekstra, Frederik J. Hes, Anouk N A van der Horst-Schrivers, Judith V.M.G. Bovée
Publikováno v:
Oncotarget, 8(9), 14525-14536. Impact Journals
Oncotarget, 8(9), 14525-14536. Impact Journals LLC
Oncotarget, 8, 14525-14536
Oncotarget
Hoekstra, A S, Hensen, E F, Jordanova, E S, Korpershoek, E, van der Horst-Schrivers, A N A, Cornelisse, C, Corssmit, E P M, Hes, F J, Jansen, J C, Kunst, H P M, Timmers, H J L M, Bateman, A, Eccles, D, Bovee, J V M G, Devilee, P & Bayley, J-P 2017, ' Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas ', Oncotarget, vol. 8, no. 9, pp. 14525-14536 . https://doi.org/10.18632/oncotarget.14649
Oncotarget, 8, 9, pp. 14525-14536
Oncotarget, 8(9), 14525-14536
Oncotarget, 8(9), 14525-14536. Impact Journals LLC
Oncotarget, 8, 14525-14536
Oncotarget
Hoekstra, A S, Hensen, E F, Jordanova, E S, Korpershoek, E, van der Horst-Schrivers, A N A, Cornelisse, C, Corssmit, E P M, Hes, F J, Jansen, J C, Kunst, H P M, Timmers, H J L M, Bateman, A, Eccles, D, Bovee, J V M G, Devilee, P & Bayley, J-P 2017, ' Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas ', Oncotarget, vol. 8, no. 9, pp. 14525-14536 . https://doi.org/10.18632/oncotarget.14649
Oncotarget, 8, 9, pp. 14525-14536
Oncotarget, 8(9), 14525-14536
// Attje S. Hoekstra 1 , Erik F. Hensen 2 , Ekaterina S. Jordanova 3 , Esther Korpershoek 4 , Anouk N.A. van der Horst-Schrivers 5 , Cees Cornelisse 3 , Eleonora P.M. Corssmit 6 , Frederik J. Hes 7 , Jeroen C. Jansen 8 , Henricus P.M. Kunst 9 , Henri
Autor:
Suzy Scholl, Sorin Dema, Noreen Gleeson, Michel Fabbro, Elodie Girard, Nathalie Mesgouez-Nebout, Mathieu Minsat, Fabrice Lecuru, Eleonor Rivin del Campo, Alexia Savignoni, Jean Marc Classe, Leanne de Koning, Virginie Fourchotte, Nina Samet, Anne Floquet, Pierre Gestraud, Katarina Koprivsek, Pierre Emmanuel Colombo, Roman Rouzier, Balázs Bálint, Christine Kerr, Charlotte Ngo, Heiko von der Leyen, Gemma G. Kenter, Jean Guillaume Feron, Nicolas de Saint-Jorre, Charles Coutant, Henry Zijlmans, Philippe Hupé, Pauline Wimberger, Aljosa Mandic, Els M.J.J. Berns, Philippe Morice, Goran Malenkovic, Madalin Margan, Coraline Dubot, Attila Kereszt, Pierre Fumoleau, Frédéric Guyon, Delphine Garbay, Nicolas Servant, Frédéric Marchal, Sanne Samuels, István Nagy, Maud Kamal, Marius Craina, Anne de la Rochefordiere, Peter Hillemanns, Eric Deutsch, Ekaterina S. Jordanova, Branislav Djuran, Alis Dema, Marina Popovic, Sylvain Dureau
Publikováno v:
EBioMedicine, 43, 253-260. Elsevier BV
EBioMedicine
EBioMedicine, Elsevier, 2019, 43, pp.253-260. ⟨10.1016/j.ebiom.2019.03.069⟩
EBioMedicine, 2019, 43, pp.253-260. ⟨10.1016/j.ebiom.2019.03.069⟩
Scholl, S, Popovic, M, de la Rochefordiere, A, Girard, E, Dureau, S, Mandic, A, Koprivsek, K, Samet, N, Craina, M, Margan, M, Samuels, S, Zijlmans, H, Kenter, G, Hillemanns, P, Dema, S, Dema, A, Malenkovic, G, Djuran, B, Floquet, A, Garbay, D, Guyon, F, Colombo, P E, Fabbro, M, Kerr, C, Ngo, C, Lecuru, F, Campo, E R D, Coutant, C, Marchal, F, Mesgouez-Nebout, N, Fourchotte, V, Feron, J G, Morice, P, Deutsch, E, Wimberger, P, Classe, J-M, Gleeson, N, von der Leyen, H, Minsat, M, Dubot, C, Gestraud, P, Kereszt, A, Nagy, I, Balint, B, Berns, E, Jordanova, E, Saint-Jorre, N D, Savignoni, A, Servant, N, Hupe, P, de Koning, L, Fumoleau, P, Rouzier, R & Kamal, M 2019, ' Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome ', EBioMedicine, vol. 43, pp. 253-260 . https://doi.org/10.1016/j.ebiom.2019.03.069
EBioMedicine
EBioMedicine, Elsevier, 2019, 43, pp.253-260. ⟨10.1016/j.ebiom.2019.03.069⟩
EBioMedicine, 2019, 43, pp.253-260. ⟨10.1016/j.ebiom.2019.03.069⟩
Scholl, S, Popovic, M, de la Rochefordiere, A, Girard, E, Dureau, S, Mandic, A, Koprivsek, K, Samet, N, Craina, M, Margan, M, Samuels, S, Zijlmans, H, Kenter, G, Hillemanns, P, Dema, S, Dema, A, Malenkovic, G, Djuran, B, Floquet, A, Garbay, D, Guyon, F, Colombo, P E, Fabbro, M, Kerr, C, Ngo, C, Lecuru, F, Campo, E R D, Coutant, C, Marchal, F, Mesgouez-Nebout, N, Fourchotte, V, Feron, J G, Morice, P, Deutsch, E, Wimberger, P, Classe, J-M, Gleeson, N, von der Leyen, H, Minsat, M, Dubot, C, Gestraud, P, Kereszt, A, Nagy, I, Balint, B, Berns, E, Jordanova, E, Saint-Jorre, N D, Savignoni, A, Servant, N, Hupe, P, de Koning, L, Fumoleau, P, Rouzier, R & Kamal, M 2019, ' Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome ', EBioMedicine, vol. 43, pp. 253-260 . https://doi.org/10.1016/j.ebiom.2019.03.069
Background There is a lack of information as to which molecular processes, present at diagnosis, favor tumour escape from standard-of-care treatments in cervical cancer (CC). RAIDs consortium ( www.raids-fp7.eu ), conducted a prospectively monitored
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b678774e6b5437f7345a5cf4b702ec4
https://pure.amc.nl/en/publications/clinical-and-genetic-landscape-of-treatment-naive-cervical-cancer-alterations-in-pik3ca-and-in-epigenetic-modulators-associated-with-suboptimal-outcome(97b3d668-59d1-4ab1-98f5-8a5731df51f7).html
https://pure.amc.nl/en/publications/clinical-and-genetic-landscape-of-treatment-naive-cervical-cancer-alterations-in-pik3ca-and-in-epigenetic-modulators-associated-with-suboptimal-outcome(97b3d668-59d1-4ab1-98f5-8a5731df51f7).html
Autor:
Awa A Gassama, S Samuels, Constantijne H. Mom, Anita G.M. Stam, Henry Zijlmans, Ekaterina S. Jordanova, AM Heeren, Jossie Rotman, G.G. Kenter, T.D. de Gruijl, Maaike C G Bleeker, Noëlle Pocorni
Publikováno v:
Journal for immunotherapy of cancer, 7(1):43. BioMed Central Ltd.
Journal for Immunotherapy of Cancer, 7(1):43. BioMed Central
Journal for Immunotherapy of Cancer
Heeren, AM, Rotman, J, Stam, A G M, Pocorni, N, Gassama, A, Samuels, S, Bleeker, M C G, Mom, CH, Zijlmans, H J M A A, Kenter, GG, Jordanova, ES & de Gruijl, TD 2019, ' Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels ', Journal for Immunotherapy of Cancer, vol. 7, no. 1, 43 . https://doi.org/10.1186/s40425-019-0526-z
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Journal for Immunotherapy of Cancer, 7(1):43. BioMed Central
Journal for Immunotherapy of Cancer
Heeren, AM, Rotman, J, Stam, A G M, Pocorni, N, Gassama, A, Samuels, S, Bleeker, M C G, Mom, CH, Zijlmans, H J M A A, Kenter, GG, Jordanova, ES & de Gruijl, TD 2019, ' Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels ', Journal for Immunotherapy of Cancer, vol. 7, no. 1, 43 . https://doi.org/10.1186/s40425-019-0526-z
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Background Cervical cancer (CxCa) is mainly a locally invading disease that metastasizes to loco-regional lymph node basins before involving distant organs in more advanced stages. Local immune potentiation of tumor-draining lymph nodes (TDLN) may th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dac1b38252c80b25221cafe4432055f7
https://pure.amc.nl/en/publications/efficacy-of-pd1-blockade-in-cervical-cancer-is-related-to-a-cd8foxp3cd25-tcell-subset-with-operational-effector-functions-despite-high-immune-checkpoint-levels(c1753c5f-7e7a-4e79-b522-5b15e7156a17).html
https://pure.amc.nl/en/publications/efficacy-of-pd1-blockade-in-cervical-cancer-is-related-to-a-cd8foxp3cd25-tcell-subset-with-operational-effector-functions-despite-high-immune-checkpoint-levels(c1753c5f-7e7a-4e79-b522-5b15e7156a17).html
Autor:
Saskia J. A. M. Santegoets, S. L. van Egmond, Chantal L. Duurland, Marij J. P. Welters, S.H. van der Burg, Ilina Ehsan, Ekaterina S. Jordanova, J J van Ham
Publikováno v:
Journal for ImmunoTherapy of Cancer, 7
Journal for Immunotherapy of Cancer, 7(1):14. BioMed Central
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for Immunotherapy of Cancer
Santegoets, S J, Duurland, C L, Jordanova, E S, van Ham, J J, Ehsan, I, van Egmond, S L, Welters, M J P & van der Burg, S H 2019, ' Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1 T cell responses ', Journal for Immunotherapy of Cancer, vol. 7, no. 1, 14, pp. 14 . https://doi.org/10.1186/s40425-019-0497-0
Journal for Immunotherapy of Cancer, 7(1):14. BioMed Central
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for Immunotherapy of Cancer
Santegoets, S J, Duurland, C L, Jordanova, E S, van Ham, J J, Ehsan, I, van Egmond, S L, Welters, M J P & van der Burg, S H 2019, ' Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1 T cell responses ', Journal for Immunotherapy of Cancer, vol. 7, no. 1, 14, pp. 14 . https://doi.org/10.1186/s40425-019-0497-0
Regulatory T cells (Tregs) may comprise different subsets allowing them to efficiently suppress different types of effector T cells. In this study, we show that high numbers of both conventional and Tbet co-expressing Foxp3hi Tregs accumulate in huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06306f742410ef57ee056abc7dadced3
http://hdl.handle.net/1887/119501
http://hdl.handle.net/1887/119501
Autor:
Fabrice Lecuru, Virginie Fourchotte, Mathieu Minsat, Jean Guillaume Feron, Nicolas Servant, Sanne Samuels, Sylvain Dureau, Katarina Koprivsek, Attila Kereszt, Roman Rouzier, István Nagy, Henry Zijlmans, Els Petronella Berns, Marina Popovic, Charlotte Ngo, Frédéric Guyon, Suzy Scholl, Peter Hillemanns, Michel Fabbro, Pierre Fumoleau, Eric Deutsch, Nicolas de Saint-Jorre, Ekaterina S. Jordanova, Jean-Marc Classe, Philippe Morice, Maud Kamal, Branislav Djuran, Pauline Wimberger, Akis Dema, Marius Craina, Noreen Gleeson, Elodie Girard, Heiko von der Leyen, Anne de la Rochefordiere, Gemma G. Kenter, Sorin Dema, Eleonor Rivin del Campo, Charles Coutant, Delphine Garbay, Goran Malenkovic, Philippe Hupé, Coraline Dubot, Nina Samet, Madalin Margan, Pierre Emmanuel Colombo, Balázs Bálint, Nathalie Mesgouez-Nebout, Alexia Savignoni, Aliosa Mandic, Christine Kerr, Leanne de Koning, Anne Floquet, Frédéric Marchal
Publikováno v:
SSRN Electronic Journal.
Background: There is a lack of information as to which molecular processes, present at diagnosis, favor tumour escape from standard-of-care treatments in cervical cancer (CC). RAIDs consortium (www.raids-fp7.eu), conducted a prospectively monitored t
Autor:
Shuchun Zhao, Eva Hoster, C. Burton, Marie José Kersten, Birgitta Sander, Norbert Schmitz, Anton Hagenbeek, John G. Gribben, Daphne de Jong, Mad-Hélénie Elsensohn, Delphine Maucort-Boulch, Laurie H. Sehn, Sharon Barrans, Ekaterina S. Jordanova, Marita Ziepert, Eva Kimby, Gilles Salles, Wolfram Klapper, Randy D. Gascoyne, Maryse Baia, Christiane Copie-Bergman, Wendy Stevens, Daniel Painter, Thierry Jo Molina, Ranjana H. Advani, Maria Calaminici, Alexandra Smith, Susanne Bens, J M Raemaekers, Fabrice Jardin, Luu Pham, Philippe Gaulard, Reiner Siebert, David Scott, Yaso Natkunam, Andreas Rosenwald
Publikováno v:
Journal of Clinical Oncology, 37(35), 3359-3368. American Society of Clinical Oncology
Journal of Clinical Oncology, 37, 3359
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2019, pp.JCO.19.00743. ⟨10.1200/JCO.19.00743⟩
Journal of clinical oncology, 37(35), 3359-3368. American Society of Clinical Oncology
Journal of Clinical Oncology, 37, 35, pp. 3359
Journal of Clinical Oncology, 2019, pp.JCO.19.00743. ⟨10.1200/JCO.19.00743⟩
Rosenwald, A, Bens, S, Advani, R, Barrans, S, Copie-Bergman, C, Elsensohn, M-H, Natkunam, Y, Calaminici, M, Sander, B, Baia, M, Smith, A, Painter, D, Pham, L, Zhao, S, Ziepert, M, Jordanova, E S, Molina, T J, Kersten, M J, Kimby, E, Klapper, W, Raemaekers, J, Schmitz, N, Jardin, F, Stevens, W B C, Hoster, E, Hagenbeek, A, Gribben, J G, Siebert, R, Gascoyne, R D, Scott, D W, Gaulard, P, Salles, G, Burton, C, de Jong, D, Sehn, L H & Maucort-Boulch, D 2019, ' Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium ', Journal of Clinical Oncology, vol. 37, no. 35, pp. 3359-3368 . https://doi.org/10.1200/JCO.19.00743
Journal of Clinical Oncology, 37, 3359
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2019, pp.JCO.19.00743. ⟨10.1200/JCO.19.00743⟩
Journal of clinical oncology, 37(35), 3359-3368. American Society of Clinical Oncology
Journal of Clinical Oncology, 37, 35, pp. 3359
Journal of Clinical Oncology, 2019, pp.JCO.19.00743. ⟨10.1200/JCO.19.00743⟩
Rosenwald, A, Bens, S, Advani, R, Barrans, S, Copie-Bergman, C, Elsensohn, M-H, Natkunam, Y, Calaminici, M, Sander, B, Baia, M, Smith, A, Painter, D, Pham, L, Zhao, S, Ziepert, M, Jordanova, E S, Molina, T J, Kersten, M J, Kimby, E, Klapper, W, Raemaekers, J, Schmitz, N, Jardin, F, Stevens, W B C, Hoster, E, Hagenbeek, A, Gribben, J G, Siebert, R, Gascoyne, R D, Scott, D W, Gaulard, P, Salles, G, Burton, C, de Jong, D, Sehn, L H & Maucort-Boulch, D 2019, ' Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium ', Journal of Clinical Oncology, vol. 37, no. 35, pp. 3359-3368 . https://doi.org/10.1200/JCO.19.00743
PURPOSE MYC rearrangement ( MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies. The impact of MYC-R on prognosis may be influenced by the MYC partner gene (immunog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f187e3c57193c0dd3133eb85e673a4a5
https://research.vumc.nl/en/publications/fc53cf9f-ed1f-4527-82bd-a61e25f84be1
https://research.vumc.nl/en/publications/fc53cf9f-ed1f-4527-82bd-a61e25f84be1
Autor:
Gre P. M. Luyten, Mark J. de Lange, Martine J. Jager, Mieke Versluis, Willem H. Zoutman, Pieter A. van der Velden, Thorbald van Hall, Rajshri N Lalai, Rogier J. Nell, Sjoerd H. van der Burg, Ekaterina S. Jordanova
Publikováno v:
Molecular Cancer Research, 16(12), 1902-1911
de Lange, M J, Nell, R J, Lalai, R N, Versluis, M, Jordanova, E S, Luyten, G P M, Jager, M J, van der Burg, S H, Zoutman, W H, van Hall, T & van der Velden, P A 2018, ' Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma ', Molecular Cancer Research, vol. 16, no. 12, pp. 1902-1911 . https://doi.org/10.1158/1541-7786.MCR-18-0114
Molecular Cancer Research, 16(12), 1902-1911. American Association for Cancer Research Inc.
Molecular Cancer Research
de Lange, M J, Nell, R J, Lalai, R N, Versluis, M, Jordanova, E S, Luyten, G P M, Jager, M J, van der Burg, S H, Zoutman, W H, van Hall, T & van der Velden, P A 2018, ' Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma ', Molecular Cancer Research, vol. 16, no. 12, pp. 1902-1911 . https://doi.org/10.1158/1541-7786.MCR-18-0114
Molecular Cancer Research, 16(12), 1902-1911. American Association for Cancer Research Inc.
Molecular Cancer Research
Uveal melanoma progression can be predicted by gene expression profiles enabling a clear subdivision between tumors with a good (class I) and a poor (class II) prognosis. Poor prognosis uveal melanoma can be subdivided by expression of immune-related
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d2d494f9f32b9aa23369d2a4d589d6b
http://hdl.handle.net/1887/87126
http://hdl.handle.net/1887/87126